Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Schott Pharma AG KGaA's average EPS without NRIGrowth Rate was -6.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 3.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 13.90% per year.
During the past 6 years, Schott Pharma AG KGaA's highest 3-Year average EPS without NRI Growth Rate was 25.10% per year. The lowest was 3.20% per year. And the median was 14.20% per year.
Schott Pharma AG KGaA (OTCPK:SHTPY) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Schott Pharma AG KGaA Earnings per Share (Diluted) Related Terms
Schott Pharma AG KGaA Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Earnings per Share (Diluted) Chart
SHTPY vs ISRG, BDX, MDLN: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's PE Ratio distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's PE Ratio falls into.
Schott Pharma AG KGaA Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Schott Pharma AG KGaA's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.27 mean?
Schott Pharma AG KGaA (SHTPY) has a Earnings per Share (Diluted) of $0.27 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Schott Pharma AG KGaA and its competitors. According to the industry distribution chart, Schott Pharma AG KGaA ranks #370 out of 655 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is Schott Pharma AG KGaA's Earnings per Share (Diluted) too high?
Schott Pharma AG KGaA's current Earnings per Share (Diluted) is $0.27. The Medical Devices & Instruments industry median Earnings per Share (Diluted) is 8.10. Schott Pharma AG KGaA's value of $0.27 is 96.7% below this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #370 out of 655 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Earnings per Share (Diluted) compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #370 out of 655 companies for Earnings per Share (Diluted). This places Schott Pharma AG KGaA in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.10. Schott Pharma AG KGaA's value of $0.27 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.10, based on 655 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Earnings per Share (Diluted) of $0.27 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Earnings per Share (Diluted) is $0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Earnings per Share (Diluted) of $0.27. The stock's GF Value™ is $5.35, compared to a current price of $4.37 — trading 18.3% below its estimated fair value. The current Earnings per Share (Diluted) is $0.27 and 96.7% below the Medical Devices & Instruments industry median of 8.10. Schott Pharma AG KGaA's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Earnings per Share (Diluted) is $0.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 18.3% below its estimated GF Value™ of $5.35.
Key valuation signals for SHTPY:
Earnings per Share (Diluted): $0.27
GF Value™: $5.35 vs. price of $4.37 (18.3% below fair value)
Industry Position: 96.7% below the Medical Devices & Instruments median (#370 of 655)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
69GF Score
Get the complete analysis for SHTPY
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
